Abstract 13793: Ten-Year Clinical Follow-up After Sirolimus-Eluting Stent Implantation
INTRODUCTION: Little is known on the “very” long-term incidence of major adverse cardiac events (MACE), target-lesion revascularization (TLR), target-vessel revascularization (TVR) and stent thrombosis (ST) after sirolimus-eluting stent (SES) implantation. We present the first study to provide a 10-year clinical follow-up in an unselected patient population who underwent SES implantation.
Methods and Results: We ran a systematic 10-year clinical follow-up in a series of 200 consecutive patients treated with unrestricted SES implantation between April 2002 and April 2003 in two Swiss hospitals. Outcomes and follow-up were obtained in all 200 patients. The cumulative 10-year MACE rate was 47% with all-cause death of 20%, cardiac death of 9%, myocardial infarction of 7%, TLR and TVR of 8% and 11% respectively. ARC-defined “definite and probable” stent thrombosis-rate was 2.5%. TLR risk was maximal between 3 to 6 years. New lesion revascularization increased throughout the study period.
CONCLUSION: Incidence of TLR was maximal 3 to 6 years after SES implantation and decreased thereafter. MACE and non-TLR revascularization rates steadily increased during the complete follow-up underlining the progression of coronary artery disease.
- © 2013 by American Heart Association, Inc.